Teva Pharmaceutical has launched the generic version of Reyataz (atazanavir) capsules in the US.
Indicated for use in combination with other antiretroviral agents, atazanavir sulfate capsules act as a protease inhibitor for the treatment of HIV-1 infection for patients six years and older weighing at least 15kg.
Go deeper with GlobalData
Teva North America commercial executive vice-president Brendan O’Grady said: “The exclusive launch of our generic version of Reyataz marks our fifth generic product offering for the treatment of HIV-1 infection.
“Antiviral medications continue to be a focus for Teva Generics, and this is an important addition to our portfolio.”
According to IMS data as of October last year, Reyataz witnessed annual sales of nearly $402m in the US.
Atazanavir is advised to be used for patients with baseline primary protease inhibitor resistance substitutions. It is not recommended for pediatric patients below the age of three months due to the risk of kernicterus.
Atazanavir sulfate capsules are also contraindicated in patients with previous records of clinically significant hypersensitivity such as Stevens-Johnson syndrome, erythema multiforme or toxic skin eruptions to any of the drug’s components.
